Navigation Links
ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR

LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of preclinical data for an orally active form of ZIO-201 (isophosphoramide mustard - IPM) at the American Association of Cancer Research meeting being held in Los Angeles. Data presented demonstrated oral availability of ZIO-201 and activity in a variety of cancer models, including those with ifosfamide (IFOS) and cyclophosphamide resistant tumors. An oral form of IPM, the primary therapeutic component of IFOS, without the toxic metabolites of IFOS, could extend the therapeutic utility of ZIO-201 well beyond that of IFOS.

"Ifosfamide has been tested as an oral drug but it is problematic at effective doses because of toxicity. Both an oral and IV form of ZIO-201 may offer clinicians an effective alternative to IFOS without the debilitating side effects associated with the other metabolites of IFOS," commented Barbara Wallner, Ph.D., Chief Technical Officer at ZIOPHARM.

About ZIO-201

ZIO-201, the active moiety of IFOS, is a bi-functional alkylator that causes irreparable inter-strand DNA cross-linking resulting in cell death. ZIO-201 is equal to or more active than IFOS in diverse cancer models. Unlike IFOS, which is a pro-drug, ZIO-201 is directly active against cancer cells. Also, unlike IFOS, ZIO-201 is not metabolized to acrolein or chloroacetaldehyde which cause bladder or central nervous system toxicities. ZIO-201 continues in a phase I trial in diverse cancers exploring maximum tolerated dose at alternate schedules. A phase II trial in advanced sarcoma continues to enroll patients. Trials in lymphoma and pediatric cancers are in the advanced planning stage. An oral form of ZIO-201 is in advanced preclinical development.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse
'"/>




Page: 1 2 3

Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
3. ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ZIOPHARM Presents Data Orally Active ZIO AACR
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... OAKS, Calif. , July 30, 2015  Amgen (NASDAQ: ... Hassan , partner and managing director of Warburg Pincus LLC, ... are pleased to welcome Fred Hassan and the ... the Amgen Board," said Robert A. Bradway , chairman ... and commitment to innovation will serve Amgen well." ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Corporation (Nasdaq: DNDN ) today reported results for ... quarter ended September 30, 2010 was $20.2 million compared to ... the nine months ended September 30, 2010 was $23.1 million ... 2009.   Revenue from sales of PROVENGE® (sipuleucel-T) ...
... EMERYVILLE, Calif., Nov. 3, 2010 Onyx Pharmaceuticals, ... results for the third quarter 2010. Onyx reported non-GAAP net ... the third quarter 2010 compared to non-GAAP net income of ... period in 2009. Non-GAAP net income excludes, among other items, ...
Cached Medicine Technology:Dendreon Reports Third Quarter 2010 Financial Results 2Dendreon Reports Third Quarter 2010 Financial Results 3Dendreon Reports Third Quarter 2010 Financial Results 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 2Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 3Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 4Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 5Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 6Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 7Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 8Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 9Onyx Pharmaceuticals Reports Third Quarter 2010 Financial Results; Japan License Leverages Worldwide Potential of Carfilzomib and Contributes $59.2 Million of License Revenue 10
(Date:8/3/2015)... ... August 03, 2015 , ... A July 13 article from The Daily ... to Release Natural Painkiller That Can Last 'For Five Weeks'" discusses the use ... the new study showed that harvesting stem cell-rich bone marrow from the hip, known ...
(Date:8/3/2015)... ... , ... Illinois Health & Science (IHS) has completed the purchase of IBA ... of IBAM NA’s cyclotron sites and research and development facilities. , “We ... well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and ...
(Date:8/3/2015)... Ramon, CA (PRWEB) , ... August 03, 2015 ... ... leading global insurance brokerage firm, announced today that Joe Williams has joined its ... development, sales, and delivering HUB's differentiated service model to his clients. Mr. Williams ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... with accountability for overall performance of the company’s Medicare and Federal Employee Programs ... Cambia’s strategy to deliver better health for members. In this role, Scott is ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... (EMSI), a leading provider of medical information, risk management and investigative services, ... evolution and direction toward focused, expert information solutions that improve business outcomes ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Institute of Medical Sciences (KIMS), a leading hospital here, ... accreditation that will// help it attract patients from abroad. ... the Australian Council for Health Care Standards International (ACHSI), ... extensive, week-long survey of KIMS facilities. KIMS has become ...
... from chronic asthma do not get proper treatment and ... ,Specialists at the Johns Hopkins Children’s Center and elsewhere ... the researchers say, because preventive therapy failure leads to ... strikes and to more complications and increased risk of ...
... tiny heating device that can be inserted inside the lungs ... or nose can help treat asthma, researchers conducting its// trial ... system in which the airways constrict making it hard to ... ,Though asthma can't be cured, it can be managed with ...
... senior and well-known scientist of America’s premier medical agency ... criminal conflict of interests.// ,Dr Trey Sutherland ... drug company as consulting fees as well as providing ... is said to have received $285,000 in payment for ...
... the anti-craving drug, Naltrexone may lessen cessation-related weight gain ... quit smoking appear //to benefit more than men. As ... on gender differences in nicotine addiction and in treatment. ... of the University of Chicago have added a drug ...
... hair-growth drug finasteride, taken by millions of balding men, ... test,// the standard screening test for prostate cancer, a ... men ranging in age from 40 to 60 years ... The Lancet and is scheduled to be published after ...
Cached Medicine News:Health News:Medication Not Available On Time To Inner-city Children 2Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
... is synthesized by the parathyroid glands ... decreased extracellular calcium concentrations. PTH prevents ... decreasing calcium excretion by the kidney. ... PTH is rapidly degraded into 4 ...
... is produced in the adrenal cortex and, ... DHEA serves as a precursor in testosterone ... androgenic activity, estimated at ~10% that of ... and in adult women, DHEA is an ...
... circulating testosterone exists as unbound or free ... to SHBG with high affinity [1], while ... Both the albumin-bound and free fractions may ... testosterone action. Measurement of the free or ...
... is a 32 kDa glycoprotein secreted by ... gland [1]. The structure of human TSH ... and placental gonadotropins, consisting of an a-subunit ... hormones and a unique beta-subunit, which confers ...
Medicine Products: